Comparative Efficacy and Safety of the Non–Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation

摘要: The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), have been shown to be at least efficacious safe conventional anticoagulants, vitamin antagonists (VKAs) (e.g., warfarin), for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Each NOAC has various advantages specific features, therefore decisions regarding appropriate require individual assessment of bleeding risk on anticoagulation VKA therapy NOACs when starting any these drugs. This review briefly describes results four clinical randomized trials discusses how they might impact practice choice patients. Moreover, this differences proposed management antithrombotic several international guidelines pragmatic issues prophylaxis.